Diligence memo · auto-generated · as of July 2, 2026

Gaingels Q Bio LLC

Gaingels Q Bio LLC looks under-valued against its niche peers and is quiet on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

Gaingels Q Bio LLC operates in Biotech / Pharma, based in BURLINGTON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Gaingels Q Bio LLC has raised $111K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $111K on 2024-03-26.

Most recent recorded round closed around 2024-03-26.

Valuation (modeled)modeled

Provath models Gaingels Q Bio LLC at approximately $597K (range $61K–$2.2M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.28× the median modeled value of Pre-Seed Biotech / Pharma companies in 2022–2024 (28 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 2.3 yr ago; this sector typically re-raises about every 15 months.

Slightly overdue versus sector cadence.

Comparablesmixed

Capital scale ranks ahead of 8% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 6% of those peers.

Closest niche peers: Gaingels Oct Bio LLC, Gaingels Alto Pharmacy LLC, Pyros Pharmaceuticals, Inc., Allander Biotechnologies, Inc., CyMon Bio, Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.